eCommons

 

DEVELOPMENT OF HDAC11 INHIBITORS AND THEIR APPLICATION IN KRAS-DRIVEN CANCERS

dc.contributor.authorSon, Se In
dc.contributor.chairLin, Hening
dc.contributor.committeeMemberSchroeder, Frank
dc.contributor.committeeMemberChang, Pamela V.
dc.date.accessioned2021-03-12T17:41:21Z
dc.date.available2022-08-27T06:00:28Z
dc.date.issued2020-08
dc.description107 pages
dc.description.abstractHDAC11 is the most recently discovered and the least studied HDAC. In recent years, it has been reported to have crucial roles in immune function, metabolism, and tumorigenesis. During my Ph.D., I have worked on developing selective HDAC11 inhibitors that do not impede other HDAC’s activity and exploring natural products as a potential HDAC11 inhibitor such as Garcinol. I then applied my developed inhibitors in different types of cancer cells. Surprisingly, HDAC11 inhibition potently suppressed the anchorage-independent growth of KRAS dependent pancreas and colon cancer cells. Our preliminary data suggest that HDAC11 inhibitors could be potential therapeutics for KRAS-driven cancers and may provide a possible solution for the long-term challenge of targeting KRAS.
dc.identifier.doihttps://doi.org/10.7298/q6z9-fq96
dc.identifier.otherSon_cornellgrad_0058F_12071
dc.identifier.otherhttp://dissertations.umi.com/cornellgrad:12071
dc.identifier.urihttps://hdl.handle.net/1813/103028
dc.language.isoen
dc.subjectGarcinol
dc.subjectHDAC11
dc.subjectHistone deacetylase
dc.subjectKRAS
dc.titleDEVELOPMENT OF HDAC11 INHIBITORS AND THEIR APPLICATION IN KRAS-DRIVEN CANCERS
dc.typedissertation or thesis
dcterms.licensehttps://hdl.handle.net/1813/59810
thesis.degree.disciplineChemistry and Chemical Biology
thesis.degree.grantorCornell University
thesis.degree.levelDoctor of Philosophy
thesis.degree.namePh. D., Chemistry and Chemical Biology

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Son_cornellgrad_0058F_12071.pdf
Size:
4.3 MB
Format:
Adobe Portable Document Format